Diagnostic Neuroimaging Research

Members

Theme Leader Kenji Ishii, M.D.
TechnologistShunsuke Fujii, R.T., M.Sci.
Adjunct ResearcherYukihisa Suzuki, M.D., Ph.D., Motoki Inaji, M.D., Ph.D., Shoko Hara, M.D., Ph.D., Kenji Ishibashi, M.D., Ph.D., Kei Wagatsuma, R.T., Ph.D., Daisuke Yoshimaru, R.T., Ph.D., Mika Tanaka, M.Sci., Masakazu Ozawa, M.D., Satomi Murakami, R.N., Shinobu Watanabe, R.N.

Keywords

PET, aging, dementia, Alzheimer's disease, Parkinson's disease, cerebrovascular disorders, epilepsy, movement disorders, cerebral blood flow and metabolism, neuroreceptors.

Major Research Titles

  1. Development of diagnostic methods for early, prodromal, and preclinical dementia
  2. Research on amyloid and tau imaging for clinical implementation
  3. Application of PET techniques for clinical gerontology research and medicine

Profile

  1. Development of diagnostic methods for early, prodromal, and preclinical dementia
    We construct a large set of brain image database with longitudinal observation and develop tools to detect fine morphological / functional deviations from estimated normal aging to detect very early change in dementia. We collaborate with Brain Bank group to conduce PET-pathology comparison which enable us to establish clinical significance of PET examinations. We tackle not only Alzheimer's disease, but also non-Alzheimer type dementias such as dementia with Lewy bodies (DLB), primary age related tauopathies (PART), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
  2. Research on amyloid and tau imaging for clinical implementation
    Since introducing [C-11]PiB-PET in 2005, we have contributed to the standardization and dissemination of amyloid PET diagnostic technology in Japan through image-pathology correlation studies, various multi-center clinical studies and clinical trials. In 2017, we compiled "The appropriate use guidelines of amyloid PET", which are currently in the fourth edition. With the clinical introduction of anti-amyloid antibody drugs for Alzheimer's disease, amyloid PET has been implemented in clinical practice nationwide. We are currently conducting clinical research to bring tau PET into practical use.
  3. Application of PET techniques for clinical gerontology research and medicine
    We apply various PET techniques to gerontology research in understanding normal brain function and its aging, and age-related brain disorders. We also provide selected PET diagnostic methods as advanced medical service of the hospital.
    Visiting Scientists: Naonori Ohno, M.D., Ph.D. (Tokyo Metropolitan Ebara Hospital), Asuka Fujino, M.D. (Tokyo Science University), Yasushi Unno, R.T. (Nihon Institute of Medical Science)Collaborating staff of TMGH: Aya M Tokumaru, M.D., Ph.D., Hiroko Matsumura, R.T.

Collaborating staff of TMGH: Aya M Tokumaru, M.D., Ph.D., Hiroko Matsumura, R.T.

References

  1. Ito K, Washimi Y, Kato T, Suzuki K, Ouchi Y, Watanabe C, Sunada Y, Kutoku Y, Ishii K, Ishii K, Kitayama M, Matsubara E, Kimura N, Takano H, Adachi H, Hara K, Kawarabayashi T, Shoji M, Sugimoto N. 18F-FDG PET for the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration: A multicenter prospective study in Japan, J Alzheimers Dis 2025;106(1):293-303
  2. Kojima N, Osuka Y, Sasai H, Shinkai S, Ishii K, Kohda N, Kobayashi Y, Kim H. Lower Firmicutes abundance in gut microbiota associated with amyloid-β positivity in older adults in Japan as assessed by positron emission tomography, PLoS One 2025;20(10):e0332801. (査読あり)
  3. Komori Y, Kurihara M, Goto R, Obata M, Ishibashi K, Ishii K, Tokumaru AM, Kanemaru K, Takeda K, Iwata A. Right temporal variant frontotemporal dementia initially presenting with gradually progressing heading disorientation: A case report, Clin Neuropsychol 2025;39(6):1742-1759
  4. Sakurai R, Kim Y, Nishinakagawa M, Hinakura K, Fujiwara Y, Ishii K. Neural correlates of age-related hearing loss: An MRI and FDG-PET study, Geriatrics & Gerontology International 2025;25(2):300-306. (査読あり) (2024IF: 2.5)
  5. Sato S, Iwata A, Ishii K, Kamiki E, Nishimoto T. [Donanemab, an Amyloid β-targeting Antibody for Early Symptomatic Alzheimer's Disease: Summary of Clinical Study Results], Brain Nerve 2025;77(8):907-92
  6. Sengoku R, Arakawa A, Matsubara T, Kameyama M, Tokumaru AM, Ishii K, Kanemaru K, Tarutani A, Hasegawa M, Iwata A, Murayama S, Saito Y. Argyrophilic Grain Disease Clinically Presenting as Progressive Supranuclear Palsy with Progressive Gait Freezing, Mov Disord Clin Pract 2025;12(8):1167-1172. (査読あり) (2024IF: 2.7)
  7. Shimasaki R, Kurihara M, Ishibashi K, Tokumaru AM, Ishii K, Iwata A. Diagnostic Challenge in Frontal Variant Alzheimer's Disease With Low Amyloid-β PET Retention, Annals of Clinical and Translational Neurology 2025;12(7):1506-1510
  8. Takenaka A, Nihashi T, Sakurai K, Notomi K, Ono H, Inui Y, Ito S, Arahata Y, Takeda A, Ishii K, Ishii K, Ito K, Toyama H, Nakamura A, Kato T. Interrater agreement and variability in visual reading of [18F] flutemetamol PET images, Annals of Nuclear Medicine 2025;39(1):68-76
  9. Arakawa A, Matsubara T, Shioya A, Hara M, Hiroyoshi Y, Kurihara M, Morimoto S, Kato T, Higashihara M, Sengoku R, Kameyama M, Kanemaru K, Tokumaru AM, Arai T, Hara N, Miyashita A, Ikeuchi T, Tarutani A, Hasegawa M, Iwata A, Toda T, Murayama S, Saito Y. Argyrophilic grain disease: epidemiology and association with cognitive decline and parkinsonism. Brain Commun. 2025 Oct 13;7(5):fcaf352
  10. Matsui H, Tamura T, Kameyama M, Omori Y, Sugihara G, Takeuchi T, Takahashi H, Furuta K. Late-Onset Oral Cenesthopathy With Dopaminergic Dysfunction: Therapeutic Response to Pramipexole in a Case With Suspected Prodromal Lewy Body Disease. Psychogeriatrics. 2025 Sep;25(5):e70088
  11. Hatano K, Kameyama M, Kurihara M, Ohse K, Goto R, Ihara R, Higashihara M, Sengoku R, Nishina Y, Kanemaru K, Saito Y, Murayama S, Iwata A. Age-related trends in amyloid positivity in Parkinson's disease without dementia. Aging (Albany NY). 2025 Aug 6;17(8):2015-2032.
  12. Matsui H, Tamura T, Kameyama M, Furuta K, Omori Y, Takeuchi T, Takahashi H, Sugihara G. Indicative biomarkers of Lewy body disease as predictors of treatment resistance in late-onset depression. Int Psychogeriatr. 2025 Sep;37(5):100043.
  13. Toyohara J, Ito M, Sakata M, Tago T, Komoda T, Yoshino H. Nonclinical investigations of a novel heart-type fatty acid-binding protein ligand, [18F]LUF: three-lot process validation, safety assessment, and radiation dosimetry. EJNMMI Radiopharm Chem. 2025 Nov 11;10(1):72
  14. Ikeda M, Ishibashi K, Amari M, Matsumura M, Kasahara H, Toyohara J, Kodaira S, Higuchi T, Ikeda Y, Tsushima Y, Okamoto K, Ishii K, Takatama M. 18F-MK-6240 uptake in cortical tau and hemorrhagic lesions in a case of Alzheimer's disease with possible crossed aphasia. eNeurologicalSci. 2025 Nov 21;41:100596
  15. Kamitaka Y, Sakata M, Oda K, Katsuki A, Kawakami H, Wagatsuma K, Ishii K. Quantitative validation of data-driven motion correction for brain PET using phantom with motion generator system. EJNMMI Phys. 2025 Dec 16;13(1):5
  16. Ishibashi K, Kurihara M, Ihara R. Both amyloid and tau assessments are desired before initiating disease-modifying therapy for Alzheimer's disease: Three real-world cases. Clin Nucl Med 2025;50(8):806-807
  17. Nakashima S, Sato K, Niimi Y, Ihara R, Ikeuchi T, Ishii K, Ito K, Iwata A, Kasuga K, Kato T, Kowa H, Nakase T, Senda M, Suzuki K, Tomita N, Tsukamoto T, Yoshiyama K, Toda T, Iwatsubo T. Characterizing Japanese Older Adults Without Dementia by Amyloid PET Status: A Comparative Study of Amyloid-Positive and Amyloid-Negative Groups from Japanese Trial-Ready Cohort Study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(1):e70242
  18. Sato K, Niimi Y, Ihara R, Ikeuchi T, Ishii K, Ito K, Iwata A, Kasuga K, Kato T, Kowa H, Nakase T, Senda M, Suzuki K, Tomita N, Tsukamoto T, Yoshiyama K, Iwatsubo T. Immediate Reactions to Amyloid PET Disclosure in Japanese Older Adults Without Dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(4)e70167
  19. Shimokawa H, Akishita M, Asada T, Katayama S, Hattori Y, Yakushiji Y, Taki Y, Murai H, Boku Y, Tsujimoto M, Umegaki H, Ogawa T, Matsumoto S, Ono K, Imon Y, Tsunemi T, Iwata A, Hanajima R, Hisahara S, Uehara T, Ishiguro T, Nakaoku Y, Ishii K, Ishiki A, Nagai Y, Teramukai S, Ihara M, Fukushima M. Baseline characteristics of patients with early Alzheimer's disease enrolled in the pivotal trial of low-intensity pulsed ultrasound (LIPUS-AD). Journal of Alzheimer's Disease Reports 2025 doi:10.1177/25424823251407541.
  20. Tsuzura K, Wagatsuma K, Kamitaka Y, Miwa K, Miyaji N, Kamiya T, Yokotsuka N, Ishii K. Phantom test procedures for a new neuro-oncological amino acid PET tracer: [18F]fluciclovine. Ann Nucl Med 2025 Jan;39(1):21-30
  21. Takenaka A, Nihashi T, Sakurai K, Notomi K, Ono H, Inui Y, Ito S, Arahata Y, Takeda A, Ishii K, Ishii K, Ito K, Toyama H, Nakamura A, Kato T & BATON Study Group. Interrater agreement and variability in visual reading of [18F]flutemetamol PET images. Ann Nucl Med 2025;39:68-76
  22. Ishibashi K, Kurihara M, Toyohara J, Ishii K, Iwata A. Pitfall of amyloid-beta PET: comparison with 18F-MK-6240 and 18F-THK5351 PET. Clin Nucl Med. 2024 Apr1;49(4):319-321
  23. Yamao T, Miwa K, KanekoY, Tkahashi N, Miyaji N, Hasegawa K, Wagatsuma K, Kamaitaka Y, Ito H, Matsuda H. Deep Learning-Driven Estimation of Centiloid Scales form Amyloid PET Images with 11C-PiB and 18F-Labeled Tracers in Alzheimer's Disease. Brain Sci. 2024 Apr 21;14(4):406.
  24. Wagatsuma K, Sakata M, Miwa K, Hamano Y, Kawakami H, Kamitaka Y, Yamao T, Miyaji N, Ishibashi K, Tago T, Toyohara J, Ishii K. Phantom and clinical evaluation of the Bayesian penalized likelihood reconstruction algorithm Q.Clear without PSF correction in amyloid PET images. EJNMMI Phys. 2024 Apr22;11(1):37
  25. Wagatsuma K, Ikemoto K, Inaji M, Kamitaka Y, Hara S, Tamura K, Miwa K, Tsuzura K, Tsuruki T, Miyaji N, Ishibashi K, Ishii K. Impact of [11C]methionine PET with Bayesian penalized likelihood reconstruction on glioma grades based on new WHO 2021 classification. Ann Nucl Med. 2024 May;38(5):400-407
  26. Yamamura T, Tamura K, Kobayashi D, Inaji M, Toyama Y, Wakimoto H, Kiyokawa J, Hara S, Tanaka Y, Nariai T, Shimizu K, Ishii K, Maehara T. Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of 11C-methionine in IDH-mutant astrocytoma. Journal of neuro-oncology 2024 Jun;168:355-365
  27. Tago T, Toyohara J. Step-by-step optimization of the radiosynthesis of the brain HDAC6 radioligand [18F]FSW-100 for clinical applications. EJNMMI Radiopharm Chem. 2024 Jun3;9(1):45.
  28. Tago T, Sakata M, Kanazawa M, Yamamoto S, Ishii K, Toyohara J. Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2193-2203
  29. Suzuki Y, Kiyosawa M, Ishii K. Measurement of Cerebral Glucose Metabolism in the Visual Cortex Predicts the Prognosis of Hemianopia. Neurorehabil Neural Repair 2024 Jun;38:437-446.
  30. Shang C, Sakurai K, Nihashi T, Arahata Y, Takeda A, Ishii K, Ishii K, Matsuda H, Ito K, Kato T, Toyama H, Nakamura A. Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods. Annals of nuclear medicine 2024 Jun;38:460-467.
  31. Niimi Y, Janelidze S, Sato K, Tomita N, Tsukamoto T, Kato T, Yoshiyama K, Kowa H, Iwata A, Ihara R, Suzuki K, Kasuga K, Ikeuchi T, Ishii K, Ito K, Nakamura A, Senda M, Day TA, Burnham SC, Iaccarino L, Pontecorvo MJ, Hansson O, Iwatsubo T. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimer's research & therapy 2024 May;16:115.
  32. Matsubara T, Ishii K, Saito Y, Tokumaru AM, Arakawa A, Hara M, Kurihara M, Sengoku R, Kanemaru K, Iwata A, Arai T, Miyashita A, Ikeuchi T, Hasegawa M, Murayama S, Saito Y. Neurofibrillary tangle-predominant dementia followed by amyloid β pathology: a clinico-radio-pathological case providing insights into current disease-modifying therapeutic strategy. Acta neuropathologica communications 2024 Jun;12:98.
  33. Hara S, Kikuta J, Takabayashi K, Kamagata K, Hayashi S, Inaji M, Tanaka Y, Hori M, Ishii K, Nariai T, Taoka T, Naganawa S, Aoki S, Maehara T. Decreased diffusivity along the perivascular space and cerebral hemodynamic disturbance in adult moyamoya disease. J Cereb Blood Flow Metab 2024 Apr:271678x241245492.
  34. Fukuda S, Wagatsuma K, Miwa K, Yakushiji Y, Kamitaka Y, Yamao T, Miyaji N, Ishii K. Optimization of penalization function in Bayesian penalized likelihood reconstruction algorithm for [18F]flutemetamol amyloid PET images. Phys Eng Sci Med 2024 Aug 12, DOI: 10.1007/s13246-024-01476-z
  35. Suzuki Y, Kiyosawa M, Wakakura M, Ishii K. Hyperactivity of the medial thalamus in patients with photophobia-associated migraine. Headache 2024;64(8):1005-1014
  36. Ishibashi K, Tago T, Kameyama M, Toyohara J, Ishii K. 18F-THK5351 uptake may not estimate neurofibrillary tangles in in vivo images: a comparison with 18F-MK6240 uptake. Clin Nucl Med. 2024 Aug1;49(8):754-756
  37. Shiio M, Maeda N, Iwata A, Ishibashi K, Ishii K, Takuma H, Ishizaka Y, Sakurai Y. Ventral Variant Posterior Cortical Atrophy with Occipito-temporal Accumulation of Tau Proteins/Astrocyte Gliosis. Case Reports. Intern Med. 2024 Sep15;63(18):2555-2565
  38. Wagatsuma K, Miwa K, Yamao T, Kamitaka Y, Akamatsu G, Nakajima K, Miyaji N, Ishibashi K, Ishii K. Development of a novel phantom for tau PET imaging. Phys Med. 2024. Jul:123:103399. doi: 10.1016/j.ejmp.2024.103399.
  39. Kondo S, Ishibashi K, Ishii K, Iwata A, Ihara R. Clinical application of 18F-THK5351 PET to image ongoing astrogliosis in MSA-P and MSA-C. Clin Nucl Med. 2024. 49(10):e503-e505
  40. Fukuda S, Wagatsuma K, Miwa K, Yakushiji Y, Kamitaka Y, Yamao T, Miyaji N, Ishii K. Optimization of penalization function in Bayesian penalized likelihood reconstruction algorithm for [18F]flutemetamol amyloid PET images. Phys Eng Sci Med. 2024. Aug 12. doi: 10.1007/s13246-024-01476-z.
  41. Tsuzura K, Wagatsuma K, Kamitaka Y, Miwa K, Miyaji N, Kamiya T, Yakostuka N, Ishii K. Phantom test procedures for a new neuro-oncological amino acid PET tracer: [18F]fluciclovine. Ann Nucl Med. 2024. Aug 29. doi: 10.1007/s12149-024-01973-x.
  42. Kurihara M, Satoh K, Shimasaki R, Hatano K, Ohse K, Taira K, Ihara R, Higashihara M, Nishina Y, Kameyama M, Iwata A. α-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnormality among patients with Lewy body disease. NPJ Parkinsons Dis. 2024 Oct 21;10(1):190
  43. Arakawa A, Murayama S, Morimoto S, Matsubara T, Sengoku R, Kameyama M, Tokumaru AM, Tarutani A, Hasegawa M, Iwata A, Toda T, Saito Y. A case of argyrophilic grain disease with an initial clinical diagnosis of Parkinson's disease. J Neurol. 2024 Oct 15. doi: 10.1007/s00415-024-12688-4.
  44. Shimasaki R, Kurihara M, Hatano K, Goto R, Taira K, Ihara R, Higashihara M, Nishina Y, Kameyama M, Iwata A. Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease: Multivariate analyses. Parkinsonism Relat Disord. 2024 Sep 1;128:107129
  45. Arakawa A, Goto R, Higashihara M, Hiroyoshi Y, Shioya A, Hara M, Orita M, Matsubara T, Sengoku R, Kameyama M, Tokumaru AM, Hasegawa M, Toda T, Iwata A, Murayama S, Saito Y. Clinicopathological study of dementia with grains presenting with parkinsonism compared with a typical case. Neuropathology. 2024 Oct;44(5):376-387.
  46. Komori Y, Kurihara M, Goto R, Obata M, Ishibashi K, Ishii K, Tokumaru AM, Kanemaru K, Takeda K, Iwata A. Right temporal variant frontotemporal dementia initially presenting with gradually progressing heading disorientation: A case report. Clin Neuropsychol. 2024 Dec 2:1-18.
  47. Kurihara M, Komatsu H, Sengoku R, Shibukawa M, Morimoto S, Matsubara T, Arakawa A, Orita M, Ishibashi K, Mitsutake A, Shibata S, Ishiura H, Adachi K, Ohse K, Hatano K, Ihara R, Higashihara M, Nishina N, Tokumaru AM, Ishii K, Saito Y, Murayama S, Kanemaru K, and Iwata A. CSF p-tau181 increases in patients with neuronal intranuclear inclusion disease without amyloid burden. Neurology, 2023 Mar 7; 100(10):e1009-e1019
  48. Miwa K, Yoshii T, Wagatsuma K, Nezu S, Kamitaka Y, Yamao T, Kobayashi R, Fukuda S, Yakushiji Y, Miyaji N, Ishii K. Impact of γ factor in the penalized function of a Bayesian penalized likelihood reconstruction (Q.Clear) to achieve high-resolution PET images. EJNMMI Phys. 2023;10(1):
  49. Ebiko Y, Tamura K, Hara S, Inaji M, Tanaka Y, Nariai T, Ishii K, Maehara T. T2-FLAIR mismatch sign correlates with 11C-methionine uptake in lower-grade diffuse gliomas. Journal of Neuro-Oncology 2023 Aug 17, https://doi.org/10.1007/s11060-023-04417-0
  50. Wagatsuma K, Miwa K, Akamatsu G, Yamao T, Kamitaka T, Sakurai M, Fujita N, Hanaoka K, Matsuda H, Ishii K: Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study. Ann Nucl Med. 2023 Sep;37(9):494-503
  51. Hatano K, Ishibashi K, Yamada K, Ishii K, Iwata A. Clinical Application of 18F-THK5351 PET to Identify Inflammatory Lesions Through Imaging Astrogliosis in a Case of Cytomegalovirus Ventriculoencephalitis. Clin Nucl Med. 2023 Oct 1;48(10):e489-e490
  52. Ishibashi K, Kurihara M, Ihara R, Higashihara M, Iwata A, Ishii K. Detailed Assessment of 18F-THK5351 Distribution Pattern in the Midbrain: Comparison ｗith Progressive Supranuclear Palsy and Corticobasal Syndrome. Clin Nucl Med. 2023. 48(10):841-846
  53. Hatano K, Ishibashi K, Kondo S, Ishii K, Iwata A. 18F-THK5351 PET can evaluate tumor extension in intravascular large B-cell lymphoma: comparison with 11C-Methionine PET and 18F-FDG PET. Clin Nucl Med. 2023. 48(4):e204-e206
  54. Kurihara M, Ishibashi K, Matsubara T, Hatano K, Ihara R, Higashihara M, Kameyama M, Tokumaru AM, Takeda K, Nishina Y, Kanemaru K, Ishii K, Iwata A. High sensitivity of asymmetric 18F-THK5351 PET abnormality in patients with corticobasal syndrome. Sci Rep. 2023. 13(1):12147.
  55. Ueda Y, Tanaka Y, Hara S, Inaji M, Ishii K, Maehara T, Nariai T. Differences in cerebral blood flow measurement using arterial spin labeling MRI between patients with moyamoya disease and patients with arteriosclerotic cerebrovascular disease. Acta Radiologica 2022 Jan 17;2841851211069245
  56. Kameyama M, Momose T, Ishibashi K, Ishii K. A novel proposal for an index for regional cerebral perfusion pressure - A theoretical approach using fluid dynamics. Fron Neurol 2022 Jan 31;12:765463
  57. Shimizu K, Tamura K, Hara S, Inaji M, Tanaka Y, Kobayashi D, Sugawara T, Wakimoto H, Nariai T, Ishii K, Sakuma I, Maehara T. Correlation of intraoperative 5-ALA-induced fluorescence intensity and preoperative 11C-Methionine PET uptake in glioma surgery. Cancers 2022 Mar 11;14(6):1449
  58. Kondo T, Hara N, Koyama S, Yada Y, Tsukita K, Nagahashi A, Ikeuchi T, Ishii K, Asada T, Yamada R, ADNI, J-ADNI, Inoue H. Detection of the polygenic architecture of neuronal Ab production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. Nature Aging 2022;2(2):125-139
  59. Toyohara J, Sakata M, Wagatsuma K, Tago T, Ishibashi K, Ishii K, Elsinga P, Ishiwata K. Test-retest reproducibility of cerebral adenosine A2A receptor quantification using [11C]preladenant. Ann Nucl Med 2022 Jan;36(1):15-23
  60. Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A2A receptor occupancy by caffeine after coffee intake in Parkinson's disease. Mov Disorders 2022 Apr;37(4):853-857
  61. Wagatsuma K, Ishibashi K, Kameyama M, Sakata M, Miwa K, Kamitaka Y, Ishii K. Decreased imaging time of amyloid PET using [18F]florbetapir can maintain quantitative accuracy. Radiological Physics and Technology 2022 Jun;15(2):116-124
  62. Imabayashi E, Tamamura N, Yamaguchi Y, Kamitaka Y, Sakata M, Ishii K. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease. Ann Nucl Med 2022 Oct;36(10):865-875. doi: 10.1007/s12149-022-01769-x
  63. Ishibashi K, Miura Y, Tago T, Toyohara J, Higashihara M, Iwata A, Ishii K. Distribution pattern of the monoamine oxidase B ligand, 18F-THK5351, in the healthy brain. Clin Nucl Med 2022 jul;47(7):e489-e495
  64. Imabayashi E, Ishii K, Toyohara J, Wagatsuma K, Sakata M, Tago T, Ishibashi K, Kojima N, Kohda N, Tokumaru AM, Kim H. Possibility of enlargement in left medial temporal areas against cerebral amyloid deposition observed during preclinical stage. Front Aging Neurosci. 2022 Apr 19;14:847094. doi: 10.3389/fnagi.2022.847094
  65. Wagatsuma K, Miwa K, Kamitaka Y, Koike E, Yamao T, Yoshii T, Kobayashi R, Nezu S, Sugamata Y, Miyaji N, Imabayashi E, Ishibashi K, Toyohara J, Ishii K. Determination of optimal reguralarization factor in Bayesian penalized likelihood reconstruction of brain PET images using [18F]FDG and [11C]PiB. Med Phys 2022 May;49(5):2995-3005
  66. Hara S, Tanaka Y, Inaji M, Hayashi S, Ishii K, Nariai T, Maehara T. Spatial coefficient of variation of arterial spin labeling MR for detecting hemodynamic disturbances measured with 15O-gas PET in patients with moyamoya disease. Neuroradiology 2022 Apr;64(4):675-684
  67. Kandiah N, Choi SH, Hu CJ, Ishii K, Kasuga K, Mok VCT. Current and future trends in biomarkers for the early detection of Alzheimer's disease in Asia: Expert opinion. JAD Reports 2022;6:699-710
  68. Yanai S, Tago T, Toyohara J, Arasaki T, Endo S. Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice. Front Pharmacol. 2022; 13:1031637
  69. Higashihara M, Ishibashi K, Tokumaru AM, Ishii K, Iwata A. Brain PET Imaging of 11C-Methionine, 18F-FDG, and 18F-THK5351 in a Case of Lymphomatoid Granulomatosis. Clin Nucl Med. 2022;47(12)e749-751
  70. Kurihara M, Komatsu H, Sengoku R, Shibukawa M, Morimoto S, Matsubara T, Arakawa A, Orita M, Ishibashi K, Mitsutake A, Shibata S, Ishiura H, Adachi K, Ohse K, Hatano K, Ihara R, Higashihara M, Nishina N, Tokumaru AM, Ishii K, Saito Y, Murayama S, Kanemaru K, and Iwata A. CSF p-tau181 increases in patients with neuronal intranuclear inclusion disease without amyloid burden. Neurology, 2023 Mar 7; 100(10):e1009-e1019
  71. Miwa K, Yoshii T, Wagatsuma K, Nezu S, Kamitaka Y, Yamao T, Kobayashi R, Fukuda S, Yakushiji Y, Miyaji N, Ishii K. Impact of γ factor in the penalized function of a Bayesian penalized likelihood reconstruction (Q.Clear) to achieve high-resolution PET images. EJNMMI Phys. 2023;10(1):4
  72. Ishibashi K, Kameyama M, Miura Y, Toyohara J, Ishii K: Head-to-head comparison of the two MAO-B radioligands, 18F-THK5351 and 11C-L-deprenyl, to visualize astrogliosis in patients with neurological disorders. Clinical Nuclear Medicine. 2021 Jan;46(1):e31-e33
  73. Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A2A receptor occupancy by long-term istradefylline administration in Parkinson's disease. Movement Disorders. 2021 Jan;36(1):268-269
  74. Yamao T, Miwa K, Wagatsuma K, Shigemoto Y, Sato, N, Akamatsu G, Ito H, Matsuda H. Centiloid scale analysis for 18F-THK5351 PET imaging in Alzheimer's disease. Phys Med. 2021;82:249-54.
  75. Matsuda H, Ito K, Ishii K, Shimosegawa E, Okazawa H, Mishina M, Mizumura S, Ishii K, Okita K, Shigemoto Y, Kato T, Takenaka A, Kaida H, Hanaoka K, Matsunaga K, Hatazawa J, Ikawa M, Tsujikawa T, Morooka M, Ishibashi K, Kameyama M, Yamao T, Miwa K, Ogawa M, Sato N. Quantitative Evaluation of 18 F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study. Front Neurol. 2021 Jan 13;11:578753.
  76. Tago T, Toyohara J, Ishii K. Preclinical Evaluation of an 18F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain. ACS Chem Neurosci. 2021 Feb 17;12(4):746-755
  77. Ikeda M, Kodaira S, Kasahara H, Takai E, Nagashima K, Fujita Y, Makioka K, Hirayanagi K, Furuta N, Fruta M, Sanada E, Kobayashi A, Harigaya Y, Nagamine S, Hattori N, Tashiro Y, Ishi K, Shimada H, Suto T, Tanaka H, Sakai Y, Yamazaki T, Tanaka Y, Aihara Y, Amari M, Yamaguchi H, Okamoro K, Takatama M, Ishii K, Higuchi T, Tsushima Y, Ikeda Y. Cerebral microbleeds, cerebrospinal fluid, and neuroimaging markers in clinical subtypes of Alzheimer's disease. Frontiers in Neurology 2021 April;12:Article543866
  78. Senda M, Ishii K, Ito K, Ikeuchi T, Matsuda H, Iwatsubo T, Iwata A, Ihara R, Suzuki K, Kasuga K, Ikari Y, Niimi Y, Arai H, Tamaoka A, Arahata Y, Itoh Y, Tachibana H, Ichimiya Y, Washizuka S, Odawara T, Ishii K, Ono K, Yokota T, Nakanishi A, Matsubara E, Mori H, Shimada H. A Japanese multicenter study on PET and other biomarkers for subjects with potential preclinical and prodromal Alzheimer's disase. J Prev Alz Dis 2021;4(8):495-502
  79. Ikeda M, Okamoto K, Suzuki K, Takai E, Kasahara H, Furuta N, Furuta M, Tashiro Y, Shimizu C, Takatama S, Naito I, Sato M, Sakai Y, Takahashi M, Amari M, Takatama M, Higuchi T, Tsushima Y, Yokoo H, Kurabayashi M, Ishibashi S, Ishii K, Ikeda Y. Siderosis in a patient of Alzheimer's disease with homozygous APOE e2 alle presenting hypobetalipoproteinemia and pathological findings of 18F-THK5351 positron emission tomography: A case report. Front Neurol 2021 July 07;12:Article 645625
  80. Kondo T, Bannno H, Okunomiya T, Amino Y, Endo K, Nakakura A, Uozumi R, Kinoshita A, Tada H, Morita S, Ishikawa H, Shindo A, Yasuda K, Taruno Y, Maki T, Suehiro T, Mori K, Ikeda M, Fjita K, Izumi Y, Kanemaru K, Ishii K, Shigenobu K, Kutoku Y, Sunada Y, Kawakatsu S, Shiota S, Watanabe T, Uchikawa O, Takahashi R, Tomimoto H, Inoue H. Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ Open 2021 Jun 30;11(6):e051343
  81. Toyohara J, Sakata M, Ishibashi K, MOssel P, Imai M, Wagatsuma K, Tago T, Imabayashi E, Colabufo NA, Luurtsema G, Ishii K. First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood-brain barrier. Ann Nucl Med 2021 Nov;35(11):1240-1252
  82. Hara S, Tanaka Y, Inaji M, Hayashi S, Ishii K, Nariai T, Maehara T. Spatial coefficient of variation of arterial spin labeling MRI for detecting hemodynamic disturbances measured with 15O-gas PET in patients with moyamoya disease. Neuroradiology 2022 Apr;64(4):675-684
  83. Toyohara J, Sakata M, Wagatsuma K, Tago T, Ishibashi K, Ishii K, Elsinga P, Ishiwata K. Test-retest reproducibility of cerebral adenosine A2A receptor quantification using [11C]preladenant. Ann Nucl Med 2022 Jan;36(1):15-23
  84. Higashihara M, Ishibashi K, Tokumaru AM, Iwata A, Ishii K. 18F-THK5351 PET Can Identify Core Lesions in Different Amyotrophic Lateral Sclerosis Phenotypes. Clin Nucl Med 2021 Dec 1;46(12):e582-e583.
  85. Ishibashi K, Miura Y, Wagatsuma K, Kameyama M, Ishii K. Brain 11C-ITMM PET to longitudinally assess type 1 metabotropic glutamate receptor availability in Alzheimer's disease. J Neuroimaging. 2021 Sep;31(5):864-868.
Text Size Invert Display Read Aloud